![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Priority Review Voucher Fees Cut for Fiscal Year 2020
Priority Review Voucher Fees Cut for Fiscal Year 2020
October 9, 2019
Effective Oct. 1, drugmakers will have to pay $2,167,116 million to redeem a priority review voucher for a newly approved drug or biologic for treatment of a rare pediatric disease, a tropical disease or for a medical countermeasure.
The cost of redeeming vouchers has dropped dramatically from over $5 million in 2012. The new fee represents an11.8 percent drop from the fiscal 2019 fee of $2.45 million.
The Congress created the PRV program in 2007, under which the FDA aims to review applications within six months.
Upcoming Events
-
21Oct